Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

110.72 +0.31 (+0.28%)
Streaming Delayed Price Updated: 2:08 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,707,647
Open 110.66
Bid (Size) 110.72 (1)
Ask (Size) 110.74 (1)
Prev. Close 110.41
Today's Range 109.88 - 111.59
52wk Range 83.05 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JPMorgan Private Bank named iShares 7-10 Year Treasury Bond ETF (NASDAQ: IEF) 
Via Benzinga
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
-0.38%
-0.38%
1 Month
-4.83%
-4.83%
3 Month
+3.82%
+3.82%
6 Month
+0.54%
+0.54%
1 Year
+20.31%
+20.31%

More News

Read More
7 Dividend Stocks to Buy (and Never Sell)
Via InvestorPlace
3 Innovative Growth Stocks to Buy for Next-Gen Profits
Via InvestorPlace
Analyst Ratings for Merck & Co
Via Benzinga
Why PDS Biotech Shares Are Jumping Today
Via Benzinga
Here's How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years
Via Benzinga
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
Via Talk Markets
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
Via Benzinga
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Via MarketBeat
Topics Death
Exposures Death Product Safety
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
Via The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Via Investor's Business Daily
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Via Benzinga
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
Via Benzinga
After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer
Via Benzinga
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
7 Stocks That Could Be the Next $2 Trillion-Dollar Companies
Via InvestorPlace
Merck Announces Third-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Doximity is an Overlooked Medical Ecosystem AI Play
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Undervalued Pharma Stocks to Buy for High Total Returns
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Via MarketBeat
Topics Economy
Exposures Economy
Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs
Via InvestorPlace
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
Via Benzinga
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.